INVASIVE DUCTAL BREAST CARCINOMA

This adverse event was reported 2721 times

These drugs are most commonly taken by patients reporting INVASIVE DUCTAL BREAST CARCINOMA:

# Drug Count
0 LETROZOLE 243
1 LETROZOLE TABLETS 206
2 METHOTREXATE SODIUM 205
3 NATALIZUMAB 190
4 METHOTREXATE 178
5 TRASTUZUMAB 161
6 ERGOCALCIFEROL 156
7 CYCLOPHOSPHAMIDE 149
8 CYCLOPHOSPHAMIDE FOR INJECTION 149
9 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 149
See all common drugs associated with INVASIVE DUCTAL BREAST CARCINOMA

INVASIVE DUCTAL BREAST CARCINOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM 3 0.1071
1 IBANDRONATE SODIUM 20 0.0064
2 VINORELBINE 43 0.0062
3 ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE 2 0.0054
4 ESTERIFIED ESTROGENS, METHYLTESTOSTERONE 2 0.0054
5 METEX 2 0.0053
6 ERGOCALCIFEROL 156 0.0052
7 TOREMIFENE CITRATE 2 0.0046
8 PEGFILGRASTIM-JMDB 2 0.0044
9 LETROZOLE TABLETS 206 0.0042
See all drugs enriched for association with INVASIVE DUCTAL BREAST CARCINOMA

INVASIVE DUCTAL BREAST CARCINOMA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Provitamin D2 Compound [EPC] 156 0.0052
1 Endoglycosidase [EPC] 9 0.0049
2 Estrogen Receptor Antagonist [EPC] 131 0.0032
3 Aromatase Inhibitor [EPC] 346 0.0030
4 Interleukin-5 Antagonist [EPC] 2 0.0029
5 Interleukin-36 Receptor Antagonist [EPC] 1 0.0025
6 Integrin Receptor Antagonist [EPC] 199 0.0023
7 HER2/neu Receptor Antagonist [EPC] 171 0.0023
8 Androgen [EPC] 40 0.0015
9 Microtubule Inhibitor [EPC] 241 0.0015
See all drug classes enriched for association with INVASIVE DUCTAL BREAST CARCINOMA